Denosumab: The era of targeted therapies in bone metastatic diseases

D. Santini, M. E. Fratto, B. Vincenzi, N. Napoli, S. Galluzzo, M. Tantardini, A. Abbruzzese, M. Caraglia, G. Tonini

Research output: Contribution to journalArticlepeer-review


This system constituted of the Receptor Activator of nuclear Factor-kB Ligand (RANKL), the Receptor Activator of Nuclear Factor-kB (RANK) and by the decoy Receptor Osteoprotegerin (OPG) plays a central role in bone resorption. Denosumab (AMG 162) is an investigational fully human monoclonal antibody with a high affinity and specificity for RANKL.This review will critically describe and discuss the recent results of clinical trial investigating denosumab in different settings of medical oncology. In particular, we will report the recently published data of clinical trials investigating denosumab in prevention of cancer treatment induced bone loss (CTIBL), in prevention of skeletal related events (SREs) in bone metastatic patients and the ongoing studies in prevention of disease recurrence in the adjuvant setting of solid tumours. The clinical data that will be reported in this review represent the first step in a path that will conduct us to explore new horizons in the field of bone health care in cancer patients.

Original languageEnglish
Pages (from-to)834-842
Number of pages9
JournalCurrent Cancer Drug Targets
Issue number7
Publication statusPublished - Nov 2009


  • Bone metastases
  • Denosumab
  • Osteoprotegerin
  • Rank
  • Rankl

ASJC Scopus subject areas

  • Drug Discovery
  • Pharmacology
  • Cancer Research


Dive into the research topics of 'Denosumab: The era of targeted therapies in bone metastatic diseases'. Together they form a unique fingerprint.

Cite this